Patent EP0033578A2 successfully refreshed from Google Patents.
EP0033578A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Hybrid cell line for producing monoclonal antibody to a human T cell antigen, antibody, and methods
Assignee: Ortho Pharmaceutical Corp
•
Filing: 1981-01-07
•
Granted: —
•
Expires: 2001-01-07
Abstract
Abstract Hybrid cell line for production of monoclonal antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF 1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
Inventors
- 👤 Patrick Chung-Shu Kung
- 👤 Gideon Goldstein
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-02 18:24
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2803; C07K16/2806; A; A61; A61P; A61P37/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/806; Y10S530/808; Y10S530/809; Y10S530/868
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
152 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with leukemic cells from a human with T-ALL, which antibody: a) reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; b) exhibits the pattern of reactivity to normal human thymocytes, E + , and E- cells shown in Figure 1; c) exhibits the pattern of reactivity to T lineage lymphocyte phenotypes shown in Table 2; d) defines a T cell population (OKT11) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hod g kins disease and psoriasis.
Claim 2
Dependent Claim
152 words
A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with leukemic cells from a human with T-ALL, which antibody: a) reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; b) exhibits the pattern of reactivity to normal human thymocytes, E + , and E- cells shown in Figure 1; c) exhibits the pattern of reactivity to T lineage lymphocyte phenotypes shown in Table 2; d) defines a T cell population (OKT11) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hod g kins disease and psoriasis.
Claim 3
Dependent Claim
16 words
Monoclonal antibody which is produced from a hybridoma having the identifying characteristics of ATCC CRL 8027.
Claim 4
Dependent Claim
16 words
Monoclonal antibody which is produced from a hybridoma having the identifying characteristics of ATCC CRL 8027.
Claim 5
Dependent Claim
144 words
An IgG monoclonal-antibody-producing hybridoma formed by fusion of spleen cells from a mouse previously immunized with leukemic cells from a human with T-ALL and cells from a mouse myeloma line, which antibody: a) reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; b) exhibits the pattern of reactivity to normal human thymocytes, E + , and E- cells shown in Figure 1; c) exhibits the pattern of reactivity to T lineage lymphocyte phenotypes shown in Table 2; d) defines a T cell population (OKT11) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hodgkins disease and psoriasis.
Claim 6
Dependent Claim
144 words
An IgG monoclonal-antibody-producing hybridoma formed by fusion of spleen cells from a mouse previously immunized with leukemic cells from a human with T-ALL and cells from a mouse myeloma line, which antibody: a) reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; b) exhibits the pattern of reactivity to normal human thymocytes, E + , and E- cells shown in Figure 1; c) exhibits the pattern of reactivity to T lineage lymphocyte phenotypes shown in Table 2; d) defines a T cell population (OKT11) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hodgkins disease and psoriasis.
Claim 7
Dependent Claim
10 words
A hybridoma having the identifying characteristics of ATCC CRL 8027.
Claim 8
Dependent Claim
10 words
A hybridoma having the identifying characteristics of ATCC CRL 8027.
Claim 9
Independent Claim
220 words
A method for preparing monoclonal antibody which: a) reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; b) exhibits the pattern of reactivity to normal human thymocytes, E + , and E' cells shown in Figure 1; c) exhibits the pattern of reactivity to T lineage lymphocyte phenotypes shown in Table 2; d) defines a T cell population (OKT11) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hodgkins disease and psoriasis. which comprises the steps of: i) immunizing mice with human leukemic T-ALL cells; ii) removing the spleens from said mice and making a suspension of spleen cells; iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; v) evaluating the supernatant in each well containing a hybridoma for the presence of the desired antibody; vi) selecting and cloning hybridomas producing the desired antibody; and vii) recovering the antibody from the supernatant above said clones.
Claim 10
Independent Claim
220 words
A method for preparing monoclonal antibody which: a) reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; b) exhibits the pattern of reactivity to normal human thymocytes, E + , and E' cells shown in Figure 1; c) exhibits the pattern of reactivity to T lineage lymphocyte phenotypes shown in Table 2; d) defines a T cell population (OKT11) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hodgkins disease and psoriasis. which comprises the steps of: i) immunizing mice with human leukemic T-ALL cells; ii) removing the spleens from said mice and making a suspension of spleen cells; iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; v) evaluating the supernatant in each well containing a hybridoma for the presence of the desired antibody; vi) selecting and cloning hybridomas producing the desired antibody; and vii) recovering the antibody from the supernatant above said clones.
Claim 11
Dependent Claim
239 words
.6. A method for preparing monoclonal antibody which: a) reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; b) exhibits the pattern of reactivity to normal human thymocytes, E + , and E- cells shown in Figure 1; c) exhibits the pattern of reactivity to T lineage lymphocyte phenotypes shown in Table 2; d) defines a T cell population (OKT11) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hodgkins disease and psoriasis. which comprises the steps of: i) immunizing mice with human leukemic T-ALL cells; ii) removing the spleens from said mice and making a suspension of the spleen cells; iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; v) evaluating the supernatant in each well containing a hybridoma for the presence of the desired antibody; vi) selecting and cloning hybridomas producing the desired antibody; vii) recovering the antibody from the supernatant above said clones; viii) transferring said clones intraperitoneally into mice; and ix) harvesting the malignant ascites or serum from said mice.
Claim 12
Dependent Claim
239 words
.6. A method for preparing monoclonal antibody which: a) reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; b) exhibits the pattern of reactivity to normal human thymocytes, E + , and E- cells shown in Figure 1; c) exhibits the pattern of reactivity to T lineage lymphocyte phenotypes shown in Table 2; d) defines a T cell population (OKT11) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hodgkins disease and psoriasis. which comprises the steps of: i) immunizing mice with human leukemic T-ALL cells; ii) removing the spleens from said mice and making a suspension of the spleen cells; iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; v) evaluating the supernatant in each well containing a hybridoma for the presence of the desired antibody; vi) selecting and cloning hybridomas producing the desired antibody; vii) recovering the antibody from the supernatant above said clones; viii) transferring said clones intraperitoneally into mice; and ix) harvesting the malignant ascites or serum from said mice.
Claim 13
Independent Claim
49 words
A method for detection of a deficiency or excess of OKT11 + cells in an individual which comprises reacting a lymphocyte composition from said individual with a 1, 2 or diagnostically-effective amount of the antibody of Claim/12 and measuring the percentage of the population which reacts with said antibody.
Claim 14
Independent Claim
41 words
A method of treatment of an OKT11 + cell excess in an individual in need of such treatment which comprises administering to said individual an amount of the antibody administerin of Claim/12 effective to reduce the amount of OKT11 + cells.
Claim 15
Dependent Claim
45 words
A method of treatment of a graft recipient to reduce or eliminate rejection of said graft which comprises administration to said recipient of an amount of the monoclonal antibody of Claim 1; 2 or 12 effective to cause said reduction or elimination of said rejection.
Claim 16
Dependent Claim
43 words
A diagnostic composition of matter for detection of OKT11 + cell excess or deficiency comprising, in admixture with a diagnostically acceptable carrier, an or amount of the antibody of Claim 1, 2 or 12 effective to detect OKT11 + cell excess or deficiency.
Claim 17
Dependent Claim
45 words
A therapeutic composition of matter comprising, in admixture with a pharmaceutically acceptable carrier, an 1, amount of the antibody of Claim 1; 2 or 12 effective to reduce the amount of OKT11 + cells in an individual having an excess of said OKT11 + cells.
Claim 18
Dependent Claim
31 words
Mouse monoclonal antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells.
Claim 19
Dependent Claim
31 words
Mouse monoclonal antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells.
Claim 20
Independent Claim
56 words
A method of preparing monoclonal antibody which reacts with essentially all normal human peripheral T cells -and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells, which comprises culturing the hybridoma ATCC CRL 8027 in a suitable medium and recovering the antibody from the supernatant above said hybridoma.
Claim 21
Independent Claim
56 words
A method of preparing monoclonal antibody which reacts with essentially all normal human peripheral T cells -and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells, which comprises culturing the hybridoma ATCC CRL 8027 in a suitable medium and recovering the antibody from the supernatant above said hybridoma.
Claim 22
Independent Claim
58 words
A method of preparing monoclonal antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes but not with normal human B cells or Null cells, which comprises injecting into a mouse the hybridoma ATCC CRL 8027 and recovering the antibody from the malignant ascites or serum of said mouse.
Claim 23
Independent Claim
58 words
A method of preparing monoclonal antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes but not with normal human B cells or Null cells, which comprises injecting into a mouse the hybridoma ATCC CRL 8027 and recovering the antibody from the malignant ascites or serum of said mouse.
Claim 24
Independent Claim
172 words
A method for preparing monoclonal antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes but not with normal human B cells or Null cells, which comprises the steps of: i) immunizing mice with human leukemic T-ALL cells; ii) removing the spleens from said mice and making a suspension of the spleen cells; iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; vi) selecting and cloning a hybridoma producing antibody which reacts with essentially all normal human peripheral T cells and with approximately 95 % of normal human thymocytes, but not with normal human B cells or Null cells; and vii) recovering the antibody from the supernatant above said clones.
Claim 25
Independent Claim
172 words
A method for preparing monoclonal antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes but not with normal human B cells or Null cells, which comprises the steps of: i) immunizing mice with human leukemic T-ALL cells; ii) removing the spleens from said mice and making a suspension of the spleen cells; iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; vi) selecting and cloning a hybridoma producing antibody which reacts with essentially all normal human peripheral T cells and with approximately 95 % of normal human thymocytes, but not with normal human B cells or Null cells; and vii) recovering the antibody from the supernatant above said clones.
Claim 26
Independent Claim
186 words
A method for preparing monoclonal antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells, which comprises the steps of: i) immunizing mice with human leukemic T-ALL cells; ii) removing the spleens from said mice and making a suspension of the spleen cells; iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; vi) selecting and cloning a hybridoma producing antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; vii) transferring said clones intraperitoneally into mice; and viii) harvesting the malignant ascites or serum from said mice, which ascites or serum contains the desired antibody.
Claim 27
Independent Claim
186 words
A method for preparing monoclonal antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells, which comprises the steps of: i) immunizing mice with human leukemic T-ALL cells; ii) removing the spleens from said mice and making a suspension of the spleen cells; iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; vi) selecting and cloning a hybridoma producing antibody which reacts with essentially all normal human peripheral T cells and with approximately 95% of normal human thymocytes, but not with normal human B cells or Null cells; vii) transferring said clones intraperitoneally into mice; and viii) harvesting the malignant ascites or serum from said mice, which ascites or serum contains the desired antibody.
Claim 28
Dependent Claim
32 words
Use in a method of treatment or diagnosis of a monoclonal antibody in accordance with Claim 1, 2, or 12, or of a composition in accordance with Claim 10 or Claim 11.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.